This proposal seeks a renewal of funding for the United States based International Breast Cancer Study Group (IBCSG) Statistical and Data Management Center, a resource that contributes to International-US collaboration in the following areas: ? Access to the IBCSG clinical database of 22,475 breast cancer patients enrolled in large-scale, randomized clinical trials with up to 26 years'maximum follow-up. ? Access to the IBCSG tissue bank database for over 2000 patients with 10-20 years'median follow-up. ? Expertise of statistical and medical investigators and collaboration in the IBCSG research agenda. This resource gives NCI an opportunity to significantly improve our understanding of treatment and prognosis of women with operable breast cancer. Participation of the IBCSG in US trials and enrollment of US patients in IBCSG trials, are essential to accrue the large number of patients needed to make real progress, especially in trials assessing treatments in relatively rare patient populations (e.g., very young women). As our understanding of the pathogenesis of breast cancer and targeted treatment responsiveness increases, the need for tailored treatment investigations focusing on more homogeneous patient cohorts also increases. Support of this proposal to continue the successful IBCSG-NCI partnership will result in enhancing the effective use of improved endocrine therapies, defining the role of chemotherapy for older and younger women, assessing maintenance metronomic chemotherapy following standard cytotoxic treatment, and evaluating chemotherapy after loco-regional recurrence. The long-range goal of the IBCSG is to determine the best possible treatments for operable breast cancer.
The specific aims of this application comprise the major areas of research toward this goal. ? To provide US-based statistical and data management collaboration for the design, conduct, analysis, and reporting of IBCSG randomized clinical trials evaluating adjuvant therapies. ? To facilitate correlative research by providing access to our uniformly treated and followed populations of patients with tissue collection at diagnosis. ? To facilitate collaboration on database studies to identify and confirm the relationship between characteristics of breast cancer patients and/or tumors and response to adjuvant therapies. ? To enhance collaboration between the IBCSG and US cooperative groups in the area of quality-of-life evaluation for patients with breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA075362-13
Application #
7753142
Study Section
Subcommittee G - Education (NCI)
Program Officer
Zujewski, Jo Anne
Project Start
1997-09-30
Project End
2010-12-31
Budget Start
2010-01-01
Budget End
2010-12-31
Support Year
13
Fiscal Year
2010
Total Cost
$482,375
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Chirgwin, Jacquie H; Giobbie-Hurder, Anita; Coates, Alan S et al. (2016) Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol 34:2452-9
Colleoni, Marco; Gray, Kathryn P; Gelber, Shari et al. (2016) Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol 34:3400-8
Bellet, Meritxell; Gray, Kathryn P; Francis, Prudence A et al. (2016) Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol 34:1584-93
Karlsson, Per; Cole, Bernard F; Price, Karen N et al. (2016) Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII. Int J Radiat Oncol Biol Phys 96:273-279
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Colleoni, Marco; Sun, Zhuoxin; Price, Karen N et al. (2016) Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 34:927-35

Showing the most recent 10 out of 67 publications